Medication Discontinuation Syndrome with Persistent Neurological Symptoms

Immediate Assessment Required

The American College of Physicians recommends ruling out medical causes first before attributing symptoms to medication withdrawal, including evaluating for thyroid dysfunction, checking for electrolyte imbalances, assessing for cardiac dysfunction, and screening for substance use 1, 2, 3, 4, 5, 6, 7
The Centers for Disease Control and Prevention (CDC) suggests considering neurological consultation if symptoms persist beyond 3 months, as this exceeds typical discontinuation syndrome duration 1

The National Institute of Mental Health indicates that benzodiazepines carry the highest risk for severe and prolonged withdrawal symptoms, including paresthesias, memory impairment, and rebound anxiety that can persist for months 1, 2
The American Psychiatric Association notes that SSRIs/SNRIs can cause discontinuation syndrome with paresthesias, cognitive difficulties, and anxiety, though typically resolving within 2-8 weeks 2, 8

The CDC recommends ensuring adequate B12, calcium, and vitamin D supplementation for tingling/paresthesias 5
The National Comprehensive Cancer Network suggests cognitive rehabilitation exercises and structured daily routines for memory issues and cognitive symptoms 3
The American College of Physicians recommends avoiding restarting benzodiazepines due to abuse/dependence risk 1, 2
The CDC advises considering medication reinstitution with proper tapering, including restarting an SSRI at 50% of the previous dose, then tapering by 25% every 1-2 weeks over 2-3 months 1, 2

The Journal of Clinical Oncology recommends monitoring response every 2-4 weeks using standardized scales, including the Patient Health Questionnaire-9 (PHQ-9) for depression 6
The Annals of Emergency Medicine suggests optimizing psychotherapy engagement, including addressing any barriers to therapy adherence 2, 5

The CDC warns against dismissing symptoms as "just anxiety" and recommends a medical workup for symptoms lasting over 3 months 5, 3
The American College of Physicians advises against restarting benzodiazepines due to the risk of dependence and severity of withdrawal symptoms 1, 2
The National Institute of Mental Health recommends against prescribing SSRIs without concurrent psychotherapy, as combination therapy achieves superior outcomes 8

The American Psychiatric Association recommends sertraline 25-50mg daily as a first-line option, with an extensive evidence base and lower QT prolongation risk than escitalopram 9, 8
The CDC suggests continuing medication for 6-12 months after symptom remission, then tapering gradually over 2-3 months to prevent recurrence 1